Setmelanotide
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Obesity Associated With Defects in Leptin-melanocortin Pathway
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Trial Timeline
Oct 21, 2024 → Oct 30, 2027
NCT ID
NCT06596135About Setmelanotide
Setmelanotide is a phase 3 stage product being developed by Rhythm Pharmaceuticals for Obesity Associated With Defects in Leptin-melanocortin Pathway. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06596135. Target conditions include Obesity Associated With Defects in Leptin-melanocortin Pathway.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06772597 | Phase 2 | Active |
| NCT06596135 | Phase 3 | Recruiting |
| NCT04966741 | Phase 3 | Completed |
| NCT04725240 | Phase 2 | Completed |
| NCT04348175 | Phase 1 | Completed |
| NCT03651765 | Phase 2/3 | Completed |
| NCT03262610 | Phase 2 | Completed |
| NCT03013543 | Phase 2 | Completed |
Competing Products
20 competing products in Obesity Associated With Defects in Leptin-melanocortin Pathway
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 52 |
| MK0557 | Merck | Phase 3 | 77 |
| AMG 786 | Amgen | Phase 1 | 32 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| Tirzepatide | Eli Lilly | Phase 2 | 52 |
| exenatide + Placebo | Eli Lilly | Approved | 85 |
| Brenipatide | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 28 |
| PG-102 | Rani Therapeutics | Phase 1 | 25 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 33 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 33 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 44 |
| Tirzepatide | Eli Lilly | Approved | 85 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 23 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 85 |